Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes

NCT05345327 is registered in ClinicalTrials.gov with The George Institute as lead sponsor.

NCT NCT05345327
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05345327 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes
Lead sponsor
The George Institute
Phase
Phase 3
Overall status
Recruiting
Start date
January 1, 2023
Completion date
June 30, 2026
Enrollment
994 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes